PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis

PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis

Tumor immunotherapy significantly rewards antigen-specific T-cell responses, which have been recognized as the foundation of adaptive immune responses. However, due to the immunosuppressive effects of the tumor microenvironment, it is still hard to activate T cells in situ. Especially, antigen-speci...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinyue Dai, Zhaoshuo Wang, Miao Fan, Huifang Liu, Xinjian Yang, Xueyi Wang, Xiaohan Zhou, Yunlu Dai, Jinchao Zhang, Zhenhua Li
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Extracellular Vesicle
Subjects:
Exosomes
Cancer vaccines
Antigen-specific T-cell immune responses
PD-1/PD-L1
Online Access:http://www.sciencedirect.com/science/article/pii/S2773041722000075
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items